Chemokines as possible therapeutic targets in metastatic melanoma

dc.contributor.authorBasson, Charlise
dc.contributor.authorSerem, June Cheptoo
dc.contributor.authorBipath, Priyesh
dc.contributor.authorHlophe, Y.
dc.date.accessioned2023-10-09T11:49:01Z
dc.date.available2023-10-09T11:49:01Z
dc.date.issued2023-07
dc.descriptionDATA AVAILABILITY STATEMENT : Data sharing not applicable to this article as no datasets were generated or analysed during the current study.en_US
dc.description.abstractBACKGROUND : Cutaneous melanoma is a relentless form of cancer which continues to rise in incidence. Currently, cutaneous melanoma is the leading cause of skin cancer-related mortality, which can mainly be attributed to its metastatic potential. The activation of chemokine axes is a major contributor to melanoma metastasis through its involvement in promoting tumour cell migration, proliferation, survival, and adhesion. This review will focus on the role of chemokines in melanoma and possible therapeutic strategies to alter chemokine activation and subsequently inhibit the activation of signalling cascades that may promote metastasis. METHODS : A literature review was conducted to evaluate chemokines as possible therapeutic targets in metastatic melanoma. RESULTS : The crosstalk between signalling pathways and immune responses in the melanoma microenvironment resembles a complex and dynamic system. Therefore, the involvement of governing chemokine axes in the promotion of cutaneous and metastatic melanoma demands a proper understanding of the tumour microenvironment in order to identify possible targets and develop appropriate treatments against melanoma. CONCLUSION : Even though chemokine axes are regarded as promising therapeutic targets, it has become increasingly evident that chemokines can play a critical role in both tumour inhibition and promotion. The inhibition of chemokine axes to inhibit signalling cascades in target cells that regulate metastasis should, therefore, be carefully approached.en_US
dc.description.departmentAnatomyen_US
dc.description.departmentPhysiologyen_US
dc.description.librarianhj2023en_US
dc.description.sponsorshipThe National Research Foundation (NRF); the School of Medicine Research Committee (RESCOM) and the University of Pretoria.en_US
dc.description.urihttp://www.wileyonlinelibrary.com/journal/cam4en_US
dc.identifier.citationBasson, C., Serem, J.C., Bipath, P. & Hlophe, Y.N. Chemokines as possible therapeutic targets in metastatic melanoma. Cancer Medicine 2023; 12: 14387-14402. doi:10.1002/cam4.6055.en_US
dc.identifier.issn2045-7634 (online)
dc.identifier.other10.1002/cam4.6055
dc.identifier.urihttp://hdl.handle.net/2263/92780
dc.language.isoenen_US
dc.publisherWileyen_US
dc.rights© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License.en_US
dc.subject.otherHealth sciences articles SDG-03
dc.subject.otherSDG-03: Good health and well-being
dc.titleChemokines as possible therapeutic targets in metastatic melanomaen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Basson_Chemokines_2023.pdf
Size:
1.95 MB
Format:
Adobe Portable Document Format
Description:
Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: